775 related articles for article (PubMed ID: 20979472)
1. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE; D'Adamo DR; Hornick JL; Dal Cin P; Antonescu CR; Jhanwar SC; Ladanyi M; Capelletti M; Rodig SJ; Ramaiya N; Kwak EL; Clark JW; Wilner KD; Christensen JG; Jänne PA; Maki RG; Demetri GD; Shapiro GI
N Engl J Med; 2010 Oct; 363(18):1727-33. PubMed ID: 20979472
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
3. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement.
Rafee S; Elamin YY; Joyce E; Toner M; Flavin R; McDermott R; Sheehy N; Hennessy B; O'Byrne K; Gleeson N; Osman N
Tumori; 2015 Apr; 101(2):e35-9. PubMed ID: 25744866
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
6. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
[TBL] [Abstract][Full Text] [Related]
8. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib targets in glioblastoma stem cells.
Junca A; Villalva C; Tachon G; Rivet P; Cortes U; Guilloteau K; Balbous A; Godet J; Wager M; Karayan-Tapon L
Cancer Med; 2017 Nov; 6(11):2625-2634. PubMed ID: 28960893
[TBL] [Abstract][Full Text] [Related]
10. Complete and Repeated Response of a Metastatic ALK-rearranged Inflammatory Myofibroblastic Tumor to Crizotinib in a Teenage Girl.
Gaudichon J; Jeanne-Pasquier C; Deparis M; Veyssière A; Heyndrickx M; Minckes O; Orbach D
J Pediatr Hematol Oncol; 2016 May; 38(4):308-11. PubMed ID: 26808369
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
12. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
13. More on crizotinib.
Orenstein JM
N Engl J Med; 2011 Feb; 364(8):777; author reply 778-9. PubMed ID: 21345112
[No Abstract] [Full Text] [Related]
14. The battle against ALK resistance: successes and setbacks.
Voena C; Chiarle R
Expert Opin Investig Drugs; 2012 Dec; 21(12):1751-4. PubMed ID: 22920921
[TBL] [Abstract][Full Text] [Related]
15. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
16. Epithelioid inflammatory myofibroblastic sarcoma treated with ALK inhibitor: a case report and review of literature.
Liu Q; Kan Y; Zhao Y; He H; Kong L
Int J Clin Exp Pathol; 2015; 8(11):15328-32. PubMed ID: 26823889
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
19. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
20. [Inflammatory myofibroblastic tumor].
Leuschner I
Pathologe; 2010 Mar; 31(2):106-8. PubMed ID: 20063099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
